Results 181 to 190 of about 14,119,663 (382)

SURFACE MARKERS ON HUMAN B AND T LYMPHOCYTES

, 1973
Mikael Jondal, George Klein
openalex   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad, Taimoon Rasheed, Momina Riaz Siddiqui, Hamza Hamid, Marwah Bintay Khalid, Haroon Shabbir, Besher Shami, Abdullah, Syed Ijlal Ahmed   +8 more
wiley   +1 more source

Expression of IgD by murine lymphocytes. Loss of surface IgD indicates maturation of memory B cells. [PDF]

, 1978
SJ Black, Wessel van der Loo, Michael R. Loken, L A Herzenberg   +3 more
openalex   +1 more source

Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes

Advances in Materials, 2017
Owen S. Fenton, Kevin J. Kauffman, James C. Kaczmarek, Rebecca L. McClellan, S. Jhunjhunwala, M. Tibbitt, Manhao Zeng, Eric A. Appel, J. R. Dorkin, Faryal F. Mir, Jung H. Yang, M. Oberli, M. Heartlein, F. Derosa, R. Langer, Daniel G. Anderson   +15 more
semanticscholar   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia, Stephane Rodriguez, Emilie Dugast, Christine Lebrun‐Frenay, Eric Thouvenot, Jérôme de Sèze, Emmanuelle Le Page, Sandra Vukusic, Inès Doghri, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabienne Le Frère, Arnaud B. Nicot, Sandrine Wiertlewski, Pierre‐Antoine Gourraud, Laure Michel, Laureline Berthelot, David‐Axel Laplaud   +20 more
wiley   +1 more source

Age-Dependent Effect of Calcitriol on Mouse Regulatory T and B Lymphocytes. [PDF]

Nutrients, 2023
Śnieżewska A, Anisiewicz A, Gdesz-Birula K, Wietrzyk J, Filip-Psurska B.   +4 more
europepmc   +1 more source

Abnormal ratio of membrane immunoglobulin classes in mice with an X-linked B-lymphocyte defect. [PDF]

, 1975
Fred D. Finkelman, Allan H. Smith, I Scher, W E Paul   +3 more
openalex   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski, Aurélie Ledreux, John E. Violette, Whitney Paustian, Stefan Sillau, John A. Thompson, Robert T. Neumann, David Ornelas, Andrew A. Monte, Layne Dylla, Adit A. Ginde, Andra M. Farcas, Christina M. Coughlan, William J. Jones, James C. Grotta, Michael W. Graner   +15 more
wiley   +1 more source

Dual B and T markers on lymphocytes in fulminant nodular lymphoma. [PDF]

, 1976
Sylvia M. Kirov, R. M. Lowenthal
openalex   +1 more source

B lymphocytes and cancer: a love-hate relationship.

Trends in Cancer, 2016
Grace J. Yuen, Ezana Demissie, S. Pillai
semanticscholar   +1 more source